| Overview |
| bs-11285R |
| FSCN3/Fascin-3 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Mouse, Rat, Dog, Sheep, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Fascin-3 |
| 401-498/498 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm |
| Fascin testis; Fascin 3; Fascin homolog 3 actin bundling protein testicular Strongylocentrotus purpuratus ; Fascin homolog 3 actin bundling protein testicular; Fascin3; FSCN 3; FSCN3; MGC94950; Testis fascin; FSCN3_HUMAN. |
| Cell adhesion to extracellular matrix is an important physiological stimulus for organization of the Actin-based cytoskeleton. Adhesion to the matrix glycoprotein Thrombospondin 1 triggers the sustained formation of F-Actin microspikes that contain the Actin-bundling protein Fascin. These structures are also implicated in cell migration, which may be an important function of Thrombospondin 1 in tissue remodelling and wound repair. Fascin bundles Actin microfilaments within dynamic cellular structures such as microspikes, stress fibers and membrane ruffles. Fascin could serve as a prognostic factor for abnormal ovarian epithelial pathology and could be a novel target for the treatment of ovarian cancer. Fascin, an Actin-bundling protein, identifies dendritic cells in the blood and in tissues. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz